Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese counterparts. On a special edition of the BioCentury This Week podcast, BioCentury’s analysts are joined by industry guests Ya-Ting Lei and Luther (Ruizhe) Zhao to discuss why the best path for biotechs in Korea and Japan is to lean into target, biology and modality risk, as well as other takeaways from the fifth BioCentury-BayHelix Biopharma Summit, which ran March 9-12 in Seoul and Daejeon, South Korea.
Lei is director of BD Asia at Merck KGaA, and Zhao is VP, China clinical analytics at Caidya.
View full story: https://www.biocentury.com/article/658776
#AsiaBiotech #SouthKoreaBiotech #BiopharmaSummit #BiotechInnovation #DrugDevelopmentStrategy
00:00 - Introduction
02:32 - Key Takeaways
05:46 - Faster Trials, Better Data
08:19 - Global Diligence, Local Success
15:13 - Cross Border Synergies
17:34 - Korean Biotech
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
